A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

•There are no approved therapies for fatty liver disease.•Dual glucagon/glucagon-like peptide-1 receptor agonism may be beneficial.•Efinopegdutide (dual agonist) improved liver fat content compared with semaglutide.•Efinopegdutide’s tolerability profile was similar to that of semaglutide.•Efinopegdutide may be an effective treatment for fatty liver disease.